بالاديا
Palladia (toceranib phosphate) is an oral multi-kinase inhibitor antineoplastic agent (receptor tyrosine kinase inhibitor) indicated for the treatment of Patnaik higher-grade (Grade II or III) recurrent or non-resectable cutaneous mast cell tumors with or without regional lymph node involvement in dogs.
الشكل الصيدلاني
Tablet
نوع المنتج
دواء
الشركة المصنعة
الحجم
Bottles of 30 round, film-coated tablets in 10 mg (blue), 15 mg (orange), and 50 mg (red) strengths
| النوع الحيواني | الجرعة | طريقة الإعطاء | المدة |
|---|---|---|---|
| Dog | 3.25 mg toceranib/kg body weight every other day | Oral (PO) | Administer every other day; dose adjustments based on clinical monitoring |
لا توجد معلومات سحب متاحة.
Treatment of recurrent or non-resectable Grade II or Grade III cutaneous mast cell tumors in dogs with or without regional lymph node involvement.
Do not use in dogs less than 24 months of age or weighing less than 5 kg.
Do not use in pregnant, lactating, or breeding dogs.
Toceranib can cause vascular and gastrointestinal toxicity, including GI perforation, pancreatitis, and proteinuria.
Routine hematology, serum biochemistry, and urinalysis (urine protein:creatinine ratio) are required before and during treatment.
Gloves must be worn when administering tablets or handling feces/urine of treated dogs.
Diarrhea, anorexia, vomiting, lethargy, weight loss, neutropenia, cutaneous depigmentation, and lameness/muscle cramping.
Palladia Prescribing Information
نشرةلا توجد أمراض مرتبطة.
لا توجد بيانات
لم تتم إضافة المعلومات بعد.
لا توجد بيانات
لم تتم إضافة المعلومات بعد.
شركة مصنعة
لا توجد بدائل متاحة.